基于1-磷酸鞘氨醇受体的冬虫夏草免疫抑制药效物质基础及作用机制研究
批准号:
82073976
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
王传喜
依托单位:
学科分类:
中药药效物质
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
王传喜
中文摘要
冬虫夏草因具有多种功效被历代医家推崇,在临床上虽被广泛用于免疫调节,但其免疫抑制的药效物质尚不明晰。冬虫夏草稀有贵重,难以获得足够量的样品是制约其药效物质研究的瓶颈。申请人前期首次从冬虫夏草中分离获得一类结构特殊且主含的脑苷脂化合物,该类化合物在体内代谢生成1-磷酸鞘氨醇后作用于1-磷酸鞘氨醇受体,从而发挥作用。虚拟靶点对接和体外活性结果提示该类化合物是冬虫夏草免疫抑制的药效物质。本项目拟在脑苷脂基因簇被阐明和冬虫夏草菌液体发酵菌丝体中含有相同脑苷脂成分的基础上,采用异源表达和液体发酵策略大量获得该类成分,运用免疫抑制经典动物模型开展药效和作用机制研究,采用成熟的[γ-35S] GTP结合实验进行靶点验证,由此阐明冬虫夏草免疫抑制的药效物质和作用机制,为产品开发和质量标准提供科学依据,从而推动中医药文化传承和产业发展。此外,异源表达和液体发酵策略,也为稀有贵重中药的研究提供方法借鉴。
英文摘要
Cordyceps sinensis has been admired by doctors in all Dynasties for its extensive pharmacological effects. And it has been widely used in clinical for immunoregulation. However, its immunosuppressive substance has not been clarified. Cordyceps sinensis is rare and precious. So, it is difficult to obtain a sufficient amount of sample from Cordyceps sinensis, which are the bottleneck of the study on the effective substances. In our previous study, the cerebrosides with distinctive structures from Cordyceps sinensis were obtained as the main ingredients for the first time. These compounds will become to sphingosine 1-phosphate in body and act on the sphingosine 1-phosphate receptor. The virtual target docking and activity results in vitro showed that these cerebrosides were the main effective substances of Cordyceps sinensis for immunosuppressive activity. Meanwhile, the gene cluster of cerebroside has been elucidated and we found that the liquid fermented mycelium of Cordyceps sinensis also contained the same cerebrosides. In our research, the strategies of heterologous expression and liquid fermentation will be used to obtain such components in large quantities. The immunosuppressive efficacy and mechanism of cerebrosides will be investigated by using the classic animal model of immunosuppression. The target of cerebrosides will be investigated in a [γ-35S] GTP functional assay. The above results will clarify the effective substances and mechanism of Cordyceps sinensis for immunosuppressive effect, which will provide a scientific basis for the development and quality control of Cordyceps sinensis. And it will promote the cultural heritage of Traditional Chinese Medicine and the development of Cordyceps sinensis industry. In addition, the strategies of heterologous expression and liquid fermentation will also provide a method for the study of rare and precious Traditional Chinese Medicine.
冬虫夏草具有免疫调节作用,早已被证实且在临床上广泛应用,冬虫夏草多糖是其免疫促进的物质基础,但其发挥免疫抑制的药效物质长期存在争议。冬虫夏草资源稀有贵重,难以获得足够量的样品是制约其药效物质研究的重要瓶颈。本项目采用合成生物学策略,将冬虫夏草脑苷脂关键基因在米曲霉异源宿主中进行了高效表达,成功构建了能够制造冬虫夏草脑苷脂的基因工程菌株。通过发酵,大量获得了主含的冬虫夏草脑苷脂。这一策略不仅实现了冬虫夏草脑苷脂的高效、绿色生产,还克服了传统冬虫夏草菌直接发酵过程中存在的周期长、条件苛刻以及产量低等难题,为后续的药效研究提供了药源保障。随后,采用实验性自身免疫性脑脊髓炎(EAE)模型对其免疫抑制活性进行评价。结果显示,冬虫夏草脑苷脂能够显著改善EAE小鼠的运动功能障碍,有效减轻小鼠脊髓的炎症反应和脱髓鞘病变。此外,在细胞和动物水平,采用免疫荧光和免疫组化等方法,研究发现冬虫夏草脑苷脂能够代谢生成1-磷酸鞘氨醇(S1P)类似物,进而功能性拮抗1-磷酸鞘氨醇受体1(S1P1),促使受体内化降解,从而减少中枢神经系统中的淋巴细胞浸润,发挥免疫抑制作用。本项目不仅首次揭示了冬虫夏草发挥免疫抑制的药效物质和作用机制,完善了冬虫夏草发挥双向免疫调节的药效物质基础,还为冬虫夏草质量标准提升和免疫抑制创新药物开发奠定了基础。同时,还为其他稀有贵重中药中复杂活性天然产物的生物合成与规模化制造提供了重要的方法学借鉴和技术支撑。本项目的研究还推动了中医药文化传承和产业发展,具有重要的社会经济效益。
基于UPLC-Q/TOF-MS导向的菌类中药冬虫夏草化学成分及抗炎活性物质研究
-
批准号:31700013
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2017
-
负责人:王传喜
-
依托单位:
国内基金
海外基金